InvestorsHub Logo
Followers 2
Posts 353
Boards Moderated 0
Alias Born 07/13/2007

Re: Chess Master post# 2606

Tuesday, 11/29/2016 2:29:14 PM

Tuesday, November 29, 2016 2:29:14 PM

Post# of 3839
I would think the partner would influence these things.

The best case is a partner who wants to explore the entire platform including dosing, indications, treatment types (oral, IV, etc.).

I would think they can exclude the CX trial since it's active and the partner could have First right of refusal on that based its outcome.

They are capital constrained right now so can't do too many exploratory studies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News